RAP 0.00% 20.5¢ resapp health limited

Ann: Change in substantial holding, page-92

  1. 2,524 Posts.
    lightbulb Created with Sketch. 272
    Respectfully, I think you may have the facts a little mixed-up.
    You say quote "
    "I take from the 2 year research agreement alone signed with MGH that our app will not be approved whilst there may be some stones left unturned. It may be unapproved for those whole 2 years?"
    This is in fact not the case at all. Put simply, my understanding is initial submission will be for approval for the app in pediatric pnemonia diagnosis, then other cough diagnosis submissions will follow. eg for other resporatory diseases in children and adults. MGH has requested RAP to make the app available to them for FURTHER research. That will have no bearing on the time taken for INITIAL FDA approval. All in my understanding and I do stand to be corrected. I trust this helps.
    MTW
 
watchlist Created with Sketch. Add RAP (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.